Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) have received an average rating of “Hold” from the seven analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $32.60.
A number of research firms have commented on EIGR. Wedbush reaffirmed an “ourperform” rating and set a $34.00 price objective on shares of Eiger BioPharmaceuticals in a research note on Monday, August 14th. Zacks Investment Research lowered shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 16th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $36.00 price objective on shares of Eiger BioPharmaceuticals in a research note on Tuesday, August 15th. BTIG Research began coverage on shares of Eiger BioPharmaceuticals in a research note on Friday, July 14th. They set a “buy” rating and a $32.00 price objective for the company. Finally, ValuEngine raised shares of Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
In related news, Director Jeffrey S. Glenn purchased 15,000 shares of Eiger BioPharmaceuticals stock in a transaction dated Friday, September 1st. The stock was acquired at an average cost of $9.53 per share, with a total value of $142,950.00. Following the completion of the transaction, the director now directly owns 31,355 shares of the company’s stock, valued at $298,813.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 28.80% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of EIGR. Hikari Power Ltd lifted its position in shares of Eiger BioPharmaceuticals by 491.0% in the second quarter. Hikari Power Ltd now owns 60,992 shares of the biotechnology company’s stock worth $482,000 after purchasing an additional 50,672 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Eiger BioPharmaceuticals in the second quarter worth approximately $272,000. LMR Partners LLP purchased a new stake in shares of Eiger BioPharmaceuticals in the second quarter worth approximately $116,000. Susquehanna International Group LLP purchased a new stake in shares of Eiger BioPharmaceuticals in the second quarter worth approximately $114,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Eiger BioPharmaceuticals by 6.4% in the second quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 871 shares in the last quarter. 59.94% of the stock is owned by institutional investors and hedge funds.
Eiger BioPharmaceuticals (NASDAQ:EIGR) traded up 1.01% during trading on Friday, hitting $10.00. 29,516 shares of the stock were exchanged. The firm’s market cap is $83.67 million. The stock’s 50-day moving average price is $8.61 and its 200-day moving average price is $8.66. Eiger BioPharmaceuticals has a 12-month low of $6.10 and a 12-month high of $14.95.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($1.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by $0.05. On average, equities analysts expect that Eiger BioPharmaceuticals will post ($5.21) EPS for the current year.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.